EP3589619A4 - Inhibiteurs de lysyl oxydases dérivés d'halogénoallylamine pyrazole et leurs utilisations - Google Patents

Inhibiteurs de lysyl oxydases dérivés d'halogénoallylamine pyrazole et leurs utilisations Download PDF

Info

Publication number
EP3589619A4
EP3589619A4 EP18761897.0A EP18761897A EP3589619A4 EP 3589619 A4 EP3589619 A4 EP 3589619A4 EP 18761897 A EP18761897 A EP 18761897A EP 3589619 A4 EP3589619 A4 EP 3589619A4
Authority
EP
European Patent Office
Prior art keywords
haloallylamine
pyrazole derivative
lysyl oxidases
derivative inhibitors
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18761897.0A
Other languages
German (de)
English (en)
Other versions
EP3589619A1 (fr
Inventor
Alison Dorothy FINDLAY
Craig Ivan Turner
Mandar Deodhar
Jonathan Stuart Foot
Wenbin ZHOU
Wolfgang JAROLIMEK
Alan Duncan Robertson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmaxis Ltd
Original Assignee
Pharmaxis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017900712A external-priority patent/AU2017900712A0/en
Application filed by Pharmaxis Ltd filed Critical Pharmaxis Ltd
Publication of EP3589619A1 publication Critical patent/EP3589619A1/fr
Publication of EP3589619A4 publication Critical patent/EP3589619A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP18761897.0A 2017-03-02 2018-03-02 Inhibiteurs de lysyl oxydases dérivés d'halogénoallylamine pyrazole et leurs utilisations Withdrawn EP3589619A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017900712A AU2017900712A0 (en) 2017-03-02 Haloallylamine pyrazole derivative inhibitors of lysyl oxidases and uses thereof
PCT/AU2018/000010 WO2018157190A1 (fr) 2017-03-02 2018-03-02 Inhibiteurs de lysyl oxydases dérivés d'halogénoallylamine pyrazole et leurs utilisations

Publications (2)

Publication Number Publication Date
EP3589619A1 EP3589619A1 (fr) 2020-01-08
EP3589619A4 true EP3589619A4 (fr) 2020-12-16

Family

ID=63369611

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18761897.0A Withdrawn EP3589619A4 (fr) 2017-03-02 2018-03-02 Inhibiteurs de lysyl oxydases dérivés d'halogénoallylamine pyrazole et leurs utilisations

Country Status (7)

Country Link
US (1) US20200069648A1 (fr)
EP (1) EP3589619A4 (fr)
JP (1) JP2020508996A (fr)
CN (1) CN110709385A (fr)
AU (1) AU2018226610A1 (fr)
CA (1) CA3054953A1 (fr)
WO (1) WO2018157190A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201716871D0 (en) 2017-10-13 2017-11-29 Inst Of Cancer Research: Royal Cancer Hospital Compounds
KR20190110736A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN112533897B (zh) 2018-08-03 2023-07-14 法玛西斯有限公司 赖氨酰氧化酶的卤代烯丙胺砜衍生抑制剂及其用途
TW202039486A (zh) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
TWI835945B (zh) 2018-12-14 2024-03-21 南韓商柳韓洋行股份有限公司 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
AU2020206477B2 (en) 2019-01-11 2022-11-10 Transthera Sciences (Nanjing), Inc. Haloallylamine compounds and application thereof
JP2022544031A (ja) * 2019-07-25 2022-10-17 ファーマクシス リミテッド リシルオキシダーゼのジフルオロハロアリルアミンスルホン誘導体阻害剤、調製方法、及びそれらの使用
CN110786834B (zh) * 2019-12-09 2022-04-05 中电健康云科技有限公司 一种基于舌象特征和bmi指数的脂肪肝预测模型
WO2021183830A1 (fr) * 2020-03-11 2021-09-16 Proda Biotech L.L.C. Méthodes de traitement de la fibrose au moyen d'activateurs de pkm2
WO2021261601A1 (fr) 2020-06-26 2021-12-30 ラクオリア創薬株式会社 Méthode de sélection d'un patient cancéreux pour lequel une polythérapie d'un rétinoïde et d'un agent de traitement du cancer sera efficace, et médicament combiné d'un rétinoïde et d'un agent de traitement du cancer
CA3225945A1 (fr) * 2021-07-16 2023-01-19 Tuan Trang Derives de sulfamoyl benzene et leurs utilisations
US12233056B2 (en) 2022-04-06 2025-02-25 Syntara Limited Lysyl oxidase inhibitors for treating myeloid malignancies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005737A2 (fr) * 2005-07-01 2007-01-11 Case Western Reserve University Inhibiteurs d'amine oxydase
US20080293936A1 (en) * 2007-05-23 2008-11-27 Elmar Reinhold Burchardt Novel inhibitors of lysyl oxidase
WO2013163675A1 (fr) * 2012-05-02 2013-11-07 Pharmaxis Ltd. Inhibiteurs de ssao 3-halogénoallylamines substituées et leurs utilisations
WO2017136871A1 (fr) * 2016-02-12 2017-08-17 Pharmaxis Ltd. Dérivé d'haloallylamines indole et azaindole comme inhibiteurs de lysyl oxydases, et leurs utilisations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252608A (en) * 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
AU618076B2 (en) * 1988-02-25 1991-12-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyloxidase
US5021456A (en) * 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
CN101917845A (zh) * 2007-11-21 2010-12-15 法马克西斯制药公司 Ssao/vap-1的卤代烯丙胺抑制剂及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005737A2 (fr) * 2005-07-01 2007-01-11 Case Western Reserve University Inhibiteurs d'amine oxydase
US20080293936A1 (en) * 2007-05-23 2008-11-27 Elmar Reinhold Burchardt Novel inhibitors of lysyl oxidase
WO2013163675A1 (fr) * 2012-05-02 2013-11-07 Pharmaxis Ltd. Inhibiteurs de ssao 3-halogénoallylamines substituées et leurs utilisations
WO2017136871A1 (fr) * 2016-02-12 2017-08-17 Pharmaxis Ltd. Dérivé d'haloallylamines indole et azaindole comme inhibiteurs de lysyl oxydases, et leurs utilisations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2018157190A1 *

Also Published As

Publication number Publication date
CN110709385A (zh) 2020-01-17
WO2018157190A1 (fr) 2018-09-07
AU2018226610A1 (en) 2019-09-05
CA3054953A1 (fr) 2018-09-07
JP2020508996A (ja) 2020-03-26
US20200069648A1 (en) 2020-03-05
WO2018157190A9 (fr) 2018-10-25
EP3589619A1 (fr) 2020-01-08

Similar Documents

Publication Publication Date Title
EP3589619A4 (fr) Inhibiteurs de lysyl oxydases dérivés d'halogénoallylamine pyrazole et leurs utilisations
ZA201805675B (en) Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof
EP3265445A4 (fr) Inhibiteurs de la lysyl oxydase-like 2 et utilisations desdits inhibiteurs
EP3810617A4 (fr) Inhibiteurs d'ectonucléotidases et leurs procédés d'utilisation
ZA202100148B (en) Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses
EP3317258A4 (fr) Inhibiteurs de lysyl oxydase-like 2 et utilisations desdits inhibiteurs
EP3325462A4 (fr) Inhibiteurs de la lysyl oxydase-like 2 et utilisations desdits inhibiteurs
AU2017900712A0 (en) Haloallylamine pyrazole derivative inhibitors of lysyl oxidases and uses thereof
AU2016900750A0 (en) Haloallylamine pyrazole derivative inhibitors of lysyl oxidases and uses thereof
AU2015901966A0 (en) Haloallylamine pyrazole derivative inhibitors of lysyl oxidases and uses thereof
AU2015901967A0 (en) Haloallylamine pyrrole and pyrazole derivative inhibitors of lysyl oxidases and uses thereof
AU2017903280A0 (en) Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof
AU2014901990A0 (en) Haloallylamine pyrazole derivative inhibitors of lysyl oxidases and uses thereof
AU2018902829A0 (en) Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof
AU2014901995A0 (en) Haloallylamine pyrrole and pyrazole derivative inhibitors of lysyl oxidases and uses thereof
AU2015900092A0 (en) Haloallylamine indole derivative inhibitors of lysyl oxidases and uses thereof
EP3595447A4 (fr) Procédés de réduction de la volatilité et de la toxicité de la clomazone
AU2015901968A0 (en) Haloallylamine inhibitors of lysyl oxidases and uses thereof
AU2013901859A0 (en) Haloallylamine pyrazole derivative inhibitors of lysyl oxidases and uses thereof
HK40001412A (en) Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof
HK40001411A (en) Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof
AU2016902593A0 (en) Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof
AU2016900478A0 (en) Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof
AU2017901429A0 (en) Haloallylamine inhibitors of amine oxidases and uses thereof
AU2014900094A0 (en) Haloallylamine indole derivative inhibitors of lysyl oxidases and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190820

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20201112

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20201106BHEP

Ipc: A61P 13/12 20060101ALI20201106BHEP

Ipc: A61P 29/00 20060101ALI20201106BHEP

Ipc: C07D 231/16 20060101AFI20201106BHEP

Ipc: A61K 31/415 20060101ALI20201106BHEP

Ipc: A61K 31/4155 20060101ALI20201106BHEP

Ipc: A61P 1/16 20060101ALI20201106BHEP

Ipc: A61P 9/00 20060101ALI20201106BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210612